10:19 ET -- Merck & Co. Inc. is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The drug maker said it will acquire Prometheus Biosciences Inc., a clinical-stage biotechnology company specializing in autoimmune disease treatments, for $200 a share, or about $10.8 billion and a 75% premium from where they closed Friday, at $114.01. Prometheus Biosciences's drug candidates include monoclonal antibodies PRA023, PRA052, PR1100 and PR2100 for treating ulcerative colitis, Crohn's disease and other immune-mediated diseases. Dow Jones & Co. owns Factiva. (ada.hui@wsj.com)

(END) Dow Jones Newswires

April 17, 2023 10:34 ET (14:34 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Feb 2025 to Mar 2025 Click Here for more Prometheus Biosciences Charts.
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Mar 2024 to Mar 2025 Click Here for more Prometheus Biosciences Charts.